No­vo Nordisk buys uni­ver­si­ty spin­out Ziy­lo — adding a po­ten­tial rem­e­dy for hy­po­glycemia to its di­a­betes pipeline

The busy R&D group at No­vo Nordisk is adding an ear­ly re­search pro­gram to its ar­se­nal of di­a­betes ther­a­pies.

In a “staged ac­qui­si­tion” that could be worth up to $800 mil­lion — with an up­front that the com­pa­nies aren’t dis­clos­ing — No­vo has gained full rights to some glu­cose bind­ing mol­e­cules de­vel­oped by Ziy­lo, a Bris­tol, UK-based biotech whose team will now work di­rect­ly with No­vo re­searchers in both Ox­ford and Copen­hagen.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.